Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 8, 2003, Pages 1139-1141

  Ghofrani, Hossein A ^a   Schermuly, Ralph T ^a   Rose, Frank ^a   Wiedemann, Ralph ^a   Kohstall, Markus G ^a   Kreckel, André ^a   Olschewski, Horst ^a   Weissmann, Norbert ^a   Enke, Beate ^a   Ghofrani, Stefanie ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Department of Internal Medicine ^*  (Germany)

Author keywords

Chronic thromboembolism; Phosphodiesterase inhibitor; Pulmonary hypertension; Sildenafil

Indexed keywords

SILDENAFIL;

ANTICOAGULANT THERAPY; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; DYSPEPSIA; ERECTILE DYSFUNCTION; EXERCISE; FEMALE; HEADACHE; HEART INDEX; HUMAN; HYPOTENSION; LONG TERM CARE; LUNG DISEASE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; SYNCOPE; VERTIGO; VISUAL IMPAIRMENT;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY EMBOLISM; TIME FACTORS;

EID: 0037446982     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200210-1157BC     Document Type: Article

References (12)

1. Jamieson SW, Auger WR, Fedullo PF, Channick RN, Kriett JM, Tarazi RY, Moser KM. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993;106:116-126.
2. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356-363.
3. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morris TA, Channick RN. Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Exp Lung Res 2000;26:287-301.
4. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465-1472.
5. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522.
6. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
7. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991;308:191-197.
8. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
9. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism: a follow-up study of the relation between the degree of right ventricle overload and the extent of perfusion defects. J Intern Med 1999;245:601-610.
10. Lewczuk J, Piszko P, Jagas J, Porada A, Wojciak S, Sobkowicz B, Wrabec K. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001;119:818-823.
11. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
12. Dantzker DR, Bower JS. Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease. Am Rev Respir Dis 1981;124:129-131.